The 23rd and 24th of July 2026 marked one of the most significant moments of formal regulatory engagement that peptide science has seen in years.
Over two days, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptide compounds being considered for potential inclusion on the 503A Bulks List, the list that governs which bulk drug substances may be used in pharmacy compounding in the United States.
Six of the seven received positive recommendations from the committee. Here is a full account of what happened.
The PCAC was not convened to decide whether these peptides should become FDA-approved medicines.
Its mandate was narrower and more specific, which was to evaluate whether each compound should be recommended for inclusion on the 503A Bulks List, which creates a regulated compounding pathway under specific conditions for state-licensed pharmacies.
A positive recommendation is advisory. It does not constitute FDA approval, and it does not immediately change how these compounds are regulated or accessed.
The FDA will take the committee’s recommendations under consideration alongside the broader evidence before making its own final determinations.
The significance of the meetings was in what they represented: two days of structured, formal, on-the-record deliberation about peptide compounds that have operated in regulatory ambiguity for years.
The first day covered BPC-157, KPV, TB-500, and MOTS-c, with discussions spanning wound healing, inflammatory conditions, metabolic health, and osteoporosis.
You can watch the full Day 1 proceedings here.
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein found in human gastric juice.
It was reviewed in the context of ulcerative colitis and received a positive recommendation.
KPV is a tripeptide fragment derived from alpha-MSH (alpha-melanocyte stimulating hormone), reviewed in relation to wound healing and inflammatory conditions.
It received a positive recommendation.
TB-500 is a synthetic fragment of thymosin beta-4, reviewed in relation to wound healing.
It received a positive recommendation.
MOTS-c is a mitochondria-derived peptide reviewed in relation to obesity and osteoporosis.
It received a positive recommendation with two committee members abstaining.
The second day covered three compounds and produced more divided outcomes. Two received positive recommendations.
You can watch the full Day 2 proceedings here.
Emideltide, commonly referred to as DSIP (delta sleep-inducing peptide), was the only compound across the two days to fail to secure a majority in favour.
With 7 votes against and 6 in favour, it did not receive a positive recommendation.
Epitalon is a synthetic tetrapeptide studied in relation to telomerase activity and circadian regulation. It received a positive recommendation.
Semax is a synthetic neuropeptide studied in relation to neurotrophic signalling and neuroprotection.
It received a positive recommendation and the strongest majority of the Day Two compounds.
Across both days, the committee’s deliberations returned repeatedly to the same set of questions.
The strength of available human clinical evidence was a consistent point of scrutiny, with the evidence base for most compounds being predominantly preclinical.
Safety data, chemical characterisation standards, and product quality requirements were also recurring concerns.
The case made by several committee members in favour of inclusion was not primarily about the strength of the research. It was more about the practical reality that these compounds are already in widespread use, and that a regulated compounding pathway, with its attendant quality controls and professional oversight, represents a safer framework than the unregulated channels through which many of them currently circulate.
To be clear about what has and has not changed: none of the seven peptides reviewed are FDA-approved, and the PCAC vote does not alter their regulatory status overnight.
It represents a formal advisory record, with six compounds now carrying positive recommendations from an FDA committee that examined each of them specifically in the context of compounding inclusion.
The FDA will now consider those recommendations as part of its own process. How long that takes, and whether the final determinations reflect the committee’s votes, remains to be seen.
Advisory recommendations inform FDA decisions. They do not guarantee them.
Understanding the regulatory landscape around peptides is one important dimension of navigating this research space responsibly. Schedule a 1:1 with one of our peptide specialists who can help you understand the research and what is relevant to your interests.
The 503A Bulks List identifies bulk drug substances that state-licensed pharmacies may use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. Its significance lies in the fact that it creates a regulated, legally defined pathway for specific substances to be compounded for individual patients. Compounds not on the list sit in a more ambiguous position in terms of regulated access through compounding pharmacies.
No. A positive PCAC recommendation is advisory input from an expert committee to the FDA. The FDA considers these recommendations as part of its own process but is not bound by them. None of the peptides reviewed have been FDA approved, and that status has not changed as a result of the committee’s votes.
Several committee members made the case that these compounds are already in widespread use through unregulated channels. The argument for inclusion on the 503A Bulks List was therefore framed not as an endorsement of the science but as a way of creating a safer, quality-controlled pathway for access that already exists in practice. As one member put it: “This is not a vote for or against peptides. It’s a vote for or against safe access.”
Emideltide was the only compound to fail to secure a majority, with 7 votes against and 6 in favour. The full deliberations are available to watch via the Day 2 link above. The recurring themes across both days, including questions around human evidence, safety data, and characterisation standards, were relevant to each compound’s discussion individually.
The FDA will consider the committee’s recommendations alongside the available evidence and make its own final determinations. There is no fixed timeline for this process. Advisory votes inform the FDA’s decisions but do not bind them. For the six compounds that received positive recommendations, the PCAC proceedings represent progress toward potential regulatory clarity rather than its conclusion.
The full Day 1 proceedings (BPC-157, KPV, TB-500, MOTS-c) are available to watch here. The full Day 2 proceedings (Emideltide, Epitalon, Semax) are available at here .
Written by Elizabeth Tito, BSc Genetics, MPH
Elizabeth is a science and medical writer specialising in peptide science, longevity medicine, mitochondrial health, metabolic optimisation and regenerative health research. With a BSc in Genetics and a Master’s in Public Health, she combines a strong scientific foundation with experience translating complex biomedical research into clear, clinically informed education for the Peptide Therapy and longevity medicine space. Her work is centred on interpreting emerging peptide, metabolic and longevity research with scientific accuracy, clinical awareness and a clear understanding of how these therapies are being discussed and applied in modern health optimisation.
Discount Applied Successfully!
Your savings have been added to the cart.
20% OFF sitewide across
UAE Peptides for a limited time
Use the promocode: SITEWIDE20
